Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Growth in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 30th, there was short interest totaling 1,115,310 shares, an increase of 160.9% from the October 15th total of 427,404 shares. Based on an average trading volume of 15,911,284 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.7% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

View Our Latest Analysis on SNTI

Senti Biosciences Trading Down 4.8%

Shares of NASDAQ SNTI traded down $0.01 during trading hours on Friday, hitting $0.14. The stock had a trading volume of 84,138 shares, compared to its average volume of 8,815,663. The firm’s 50-day moving average price is $0.26 and its two-hundred day moving average price is $0.68. Senti Biosciences has a 52 week low of $0.14 and a 52 week high of $2.88.

Senti Biosciences (NASDAQ:SNTI – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.08). The business had revenue of $0.02 million during the quarter.

About Senti Biosciences

(Get Free Report)

Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.

Further Reading

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.